Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En studie av Buntanetap hos deltakere med PD

28. oktober 2026 oppdatert av: Annovis Bio Inc.

En åpen klinisk studie som undersøker langsiktig sikkerhet av Buntanetap i behandlingen av deltakere med Parkinsons sykdom

This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study. This study will be conducted with two cohorts. Cohort 1 will enroll via invitation only for PD participants who have previously participated in buntanetap clinical trials. Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment. Qualified participants will receive buntanetap 30mg QD after a screening period of up to 42 days.

Studieoversikt

Status

Rekruttering

Intervensjon / Behandling

Detaljert beskrivelse

This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study. This study will be conducted with two cohorts. Cohort 1 will enroll via invitation only for PD participants who have previously participated in buntanetap clinical trials. Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment. Qualified participants will receive buntanetap 30mg QD after a screening period of up to 42 days. MMSE, MoCA, C-SSRS, and MDS-UPDRS will be assessed by clinicians who have successfully completed the requisite certifications/trainings for each assessment. Each participant shall be assessed by the same clinician throughout the study. Cohort 1 participants will stop standard of care Parkinson's medications 12h before baseline and annual clinical visits to ensure clinical OFF-state during visit. Cohort 2 participants will stop standard of care Parkinson's medications 12h before all clinic visits. The night before the baseline and annual clinic visits (or early termination visit), Cohort 2 participants will return DBS settings to their initial baseline settings.

Studietype

Intervensjonell

Registrering (Antatt)

500

Fase

  • Fase 2
  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • Alabama
      • Birmingham, Alabama, Forente stater, 35233
        • Rekruttering
        • University of Alabama at Birmingham
        • Ta kontakt med:
        • Hovedetterforsker:
          • Natividad Stover, M.D.
    • Arizona
      • Sun City, Arizona, Forente stater, 85351
        • Rekruttering
        • Banner Sun Health Research Institute - Cleo Roberts Center for Clinical Research
        • Hovedetterforsker:
          • Sara Dhanani, M.D.
        • Ta kontakt med:
    • California
      • Fountain Valley, California, Forente stater, 92708
        • Rekruttering
        • Parkinson's & Movement Disorder Institute (PMDI) - Orange County Office
        • Hovedetterforsker:
          • Daniel Truong, M.D.
        • Ta kontakt med:
          • Evan Moreno-Davis
          • Telefonnummer: 714-378-5074
          • E-post: evan@pmdi.org
    • Colorado
      • Englewood, Colorado, Forente stater, 80113
        • Rekruttering
        • Cenexel Rocky Mountain Clinical Research
        • Ta kontakt med:
        • Hovedetterforsker:
          • Meagen Salinas, M.D.
    • Connecticut
      • Stamford, Connecticut, Forente stater, 06824
        • Rekruttering
        • New England Institute for Clinical Research (Ki Health Partners)
        • Ta kontakt med:
        • Hovedetterforsker:
          • Peter McAllister, M.D.
    • Florida
      • Aventura, Florida, Forente stater, 33180
        • Rekruttering
        • First Choice Neurology - Aventura Neurologic Associates
        • Hovedetterforsker:
          • Jonathan Cross, M.D.
        • Ta kontakt med:
      • Daytona Beach, Florida, Forente stater, 32117
        • Rekruttering
        • Arrow Clinical Trials
        • Ta kontakt med:
        • Hovedetterforsker:
          • David Billmeier, M.D.
      • DeLand, Florida, Forente stater, 32720
        • Rekruttering
        • Accel Clinical Sites-Georgia LLC dba Accel Research Sites-Lake Oconee CRU
        • Hovedetterforsker:
          • Bruce Rankin, D.O.
        • Ta kontakt med:
      • Miami, Florida, Forente stater, 33172
      • Miami, Florida, Forente stater, 33015
        • Har ikke rekruttert ennå
        • Ezy Medical Research Co.
        • Ta kontakt med:
      • Ocala, Florida, Forente stater, 34470
        • Rekruttering
        • Renstar Medical Research
        • Hovedetterforsker:
          • Annette Nieves, M.D.
        • Ta kontakt med:
      • Tampa, Florida, Forente stater, 33613
        • Rekruttering
        • University of South Florida (USF) - University of South Florida College of Medicine - Parkinson's Di
        • Ta kontakt med:
        • Hovedetterforsker:
          • Robert Hauser, M.D., MBA
      • Winter Park, Florida, Forente stater, 32789
        • Rekruttering
        • Conquest Research
        • Ta kontakt med:
        • Hovedetterforsker:
          • Rekha Gandhi, M.D.
    • Georgia
      • Decatur, Georgia, Forente stater, 30030
        • Rekruttering
        • iResearch Atlanta
        • Ta kontakt med:
        • Hovedetterforsker:
          • Kimball Johnson, M.D.
    • Indiana
      • Indianapolis, Indiana, Forente stater, 46256
        • Rekruttering
        • Josephson Wallack Munshower Neurology, P.C.
        • Hovedetterforsker:
          • Kristi George, M.D.
        • Ta kontakt med:
    • Kansas
      • Kansas City, Kansas, Forente stater, 66160
        • Rekruttering
        • University of Kansas Medical Center (KUMC) - School of Medicine - Parkinson's Disease and Movement D
        • Ta kontakt med:
        • Hovedetterforsker:
          • Rajesh Pahwa, M.D.
    • Michigan
      • Farmington Hills, Michigan, Forente stater, 48334
        • Rekruttering
        • Quest Research Institute
        • Hovedetterforsker:
          • Aaron Ellenbogen, D.O.
        • Ta kontakt med:
    • New York
      • New York, New York, Forente stater, 10019
        • Rekruttering
        • Mount Sinai Hospital
        • Hovedetterforsker:
          • Joohi Jimenez-Shahed, M.D.
        • Ta kontakt med:
    • North Carolina
      • Durham, North Carolina, Forente stater, 27710
        • Rekruttering
        • Duke Department of Neurosurgery
        • Hovedetterforsker:
          • Kyle Mitchell, M.D.
        • Ta kontakt med:
    • Ohio
      • Columbus, Ohio, Forente stater, 43210
        • Rekruttering
        • The Ohio State University Wexner Medical Center
        • Hovedetterforsker:
          • Zachary Jordan, M.D.
        • Ta kontakt med:
    • Oklahoma
      • Tulsa, Oklahoma, Forente stater, 74136
        • Rekruttering
        • The Movement Disorder Clinic of Oklahoma
        • Ta kontakt med:
        • Hovedetterforsker:
          • Kevin Klos, M.D.
    • Pennsylvania
      • Willow Grove, Pennsylvania, Forente stater, 19090
        • Rekruttering
        • Abington Neurology
        • Hovedetterforsker:
          • David Weisman, M.D.
        • Ta kontakt med:
    • South Carolina
      • Charleston, South Carolina, Forente stater, 29401
        • Rekruttering
        • Medical University of South Carolina (MUSC) - The Murray Center for Research on Parkinson's Disease
        • Ta kontakt med:
        • Hovedetterforsker:
          • Vanessa Hinson, M.D., PhD
    • Tennessee
      • Cordova, Tennessee, Forente stater, 38018
        • Rekruttering
        • Neurology Clinic, P.C.
        • Ta kontakt med:
        • Hovedetterforsker:
          • Kendrick Henderson, M.D.
      • Memphis, Tennessee, Forente stater, 38157
        • Rekruttering
        • Veracity Neuroscience LLC
        • Ta kontakt med:
        • Hovedetterforsker:
          • Mark LeDoux, M.D., PhD
    • Texas
      • Round Rock, Texas, Forente stater, 78681
        • Rekruttering
        • Central Texas Neurology
        • Ta kontakt med:
        • Hovedetterforsker:
          • Elizabeth Peckham, M.D.
    • Virginia
      • Charlottesville, Virginia, Forente stater, 22903
        • Rekruttering
        • University of Virginia Health System (UVAHS) - Adult Neurology Clinic
        • Hovedetterforsker:
          • Binit Shah, M.D.
        • Ta kontakt med:
    • Washington
      • Spokane, Washington, Forente stater, 99202
        • Rekruttering
        • Inland Northwest Research
        • Hovedetterforsker:
          • Jason Aldred, M.D.
        • Ta kontakt med:
    • Wisconsin
      • Milwaukee, Wisconsin, Forente stater, 53226
        • Rekruttering
        • Medical College of Wisconsin
        • Ta kontakt med:
        • Hovedetterforsker:
          • Karen Blindauer, M.D.

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

40 år til 85 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Diagnosis of idiopathic PD according to MDS Clinical Diagnostic Criteria for Parkinson's Disease (Postuma et al., 2015) and

    a. Cohort 1: Participated in a prior PD clinical trial with buntanetap. i. A legally authorized representative is required for any participant whose MMSE <21 at screening.

    b. Cohort 2: Has been receiving DBS treatment in either 1) the subthalamic nucleus or 2) the globus pallidus internus for at least 12 months after a successful DBS surgery that achieved the goal.

    i. Female or male adults aged 40 to 85 years. ii. H&Y stage 1-3 in ON state. iii. MMSE 21-30 at screening and baseline.

  2. Have a support person who will accompany the participant on study visits at designated times.

  3. Female participants of childbearing potential* must have a negative urine pregnancy test at screening, must be non-lactating, and must agree to use a highly effective method of contraception (i.e., a method resulting in a failure rate of less than 1% per year when used consistently and correctly) during the trial and for one month after the last dose of trial treatment, such as:

    1. Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,

    2. Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,

    3. Intrauterine device (IUD),

    4. Intrauterine hormone-releasing system (IUS),

    5. Bilateral tubal occlusion,

    6. Vasectomized partner (a vasectomized partner is a highly effective contraception method provided that the partner is the sole male sexual partner of the participant, and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used),

    7. Sexual abstinence (sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatment. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant).

      • Non-childbearing potential includes surgically sterilized or postmenopausal with no menstrual bleeding for at least one year prior to study start.

    Protocol ANVS-25002 Ver. 2.1; 09-23-2025 Confidential Page 30 of 54

  4. Male participants must be sterile or sexually inactive or agree not to father a child during the study and one month after the last dose of study medication and must agree to use a barrier method for contraception. Female partners of male participants must adopt a highly effective method of contraception with a failure rate of less than 1% per year when used consistently and correctly such as:

    1. Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,
    2. Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,
    3. IUD,
    4. IUS,
    5. Bilateral tubal occlusion.
  5. No evidence of current suicidal ideation or previous suicide attempt in the past month as evaluated in the C-SSRS.

  6. Stability of permitted medications for at least 4 weeks prior to screening. Refer to Concomitant Medications section above for details on prohibited and permitted medications.

    1. Standard of care anti-parkinsonian medication,
    2. Cholinesterase inhibitors and/or memantine medication,
    3. Anticonvulsant medications used for epilepsy or mood stabilization, or neuropathic pain indications, and have not had a breakthrough seizure 3 years prior to screening,
    4. Mood-stabilizing psychotropic agents including, but not limited to, lithium,
  7. Adequate visual and hearing ability (physical ability to perform all the study assessments).

  8. Good general health with no disease expected to interfere with the study.

Exclusion Criteria:

  1. Cohort 1 only: Is currently receiving DBS treatment. (Participant may enroll in Cohort 2 if they meet the corresponding inclusion/exclusion criteria).

  2. A history of psychiatric disorder such as schizophrenia, bipolar disorder, or major depression according to the criteria of the most current version of the Diagnostic and Statistical Manual of Mental Disorders (DSM), unless their symptoms have been mild, and they are stable on treatment or no longer need treatment. Mild depression or history of depression that is stable on treatment with selective serotonin reuptake inhibitors (SSRI) or serotonin and norepinephrine reuptake inhibitors (SNRI) medication at a stable dose is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.

  3. A history of seizure disorder. If stable on medication, it is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.

  4. A history or current evidence of long QT syndrome, Fridericia's formula corrected QT (QTcF) interval ≥ 450 ms for men and ≥ 460 ms for women, or torsades de pointes.

  5. Bradycardia (<50 bpm) or tachycardia (>100 bpm) on the ECG at screening and deemed medically significant by the PI.

    Protocol ANVS-25002 Ver. 2.1; 09-23-2025 Confidential Page 31 of 54

  6. Uncontrolled Type-1 or Type-2 diabetes. A participant with hemoglobin subunit alpha 1c (HbA1c) levels up to 7.5% can be enrolled if the investigator believes the participant's diabetes is under control.

  7. Clinically significant renal (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] <50 mL/min/BSA [body surface area]) or hepatic impairment (Alkaline phosphatase [ALP] > 2.0X the upper limit of normal [ULN] and/or total bilirubin > 2.0X ULN).

  8. Any clinically significant abnormal laboratory values. Participants with liver function tests (aspartate aminotransferase [AST] or alanine aminotransferase [ALT]) greater than twice ULN will be excluded.

  9. Is at imminent risk of self-harm, based on clinical interview and responses on the C-SSRS, or of harm to others in the opinion of the investigators. Participants must be excluded if they report suicidal ideation with intent, with or without a plan or method (e.g., positive response to Items 4 or 5 in assessment of suicidal ideation on C-SSRS) in the past 2 months, or suicidal behavior in the past 6 months.

  10. Cancer or has had a malignant tumor within the past year, except participants who underwent potentially curative therapy with no evidence of recurrence (participants with stable untreated cancer are not excluded).

  11. Alcohol / Substance use disorder, moderate to severe, in the last 5 years according to the most current version of the DSM.

  12. Participation in another clinical trial with an investigational agent and have taken at least one dose of study medication, unless unblinded on placebo, within 4 weeks prior to the start of screening, or five half-lives of the investigational drug, whichever is greater. The end of a previous investigational trial is the date the last dose of an investigational agent was taken.

  13. A learning disability or developmental delay.

  14. Participants whom the site PI deems to be otherwise ineligible.

  15. A known allergy to the investigational drug or any of its components.

    Inactive ingredients of the investigational medicinal product:

    • Silicified microcrystalline cellulose
    • Dibasic calcium phosphate dihydrate
    • Mannitol
    • Stearic acid
    • Hypromellose (capsule shells structure)
    • Titanium dioxide (opacifier of the capsule shells)
  16. Is currently pregnant, breast-feeding, and/or lactating.

  17. Uncontrolled hypertension (systolic >160mmHg and/or diastolic >95mmHg) or hypotension (systolic <90mmHg and/or diastolic <60 mmHg) and deemed medically significant by the PI.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Cohort 1 - buntanetap

Cohort 1 will enroll via invitation only for PD participants who have previously participated in bun

buntanetap capsules 30 mg by mouth daily

Eksperimentell: Cohort 2 - buntanetap

Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment.

buntanetap capsules 30 mg by mouth daily

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Safety of buntanetap
Tidsramme: 36-months of treatment

Safety assessments of participants with PD receiving treatment with buntanetap

36-months of treatment
Adverse Events (AE)
Tidsramme: 36-months of treatment

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention

36-months of treatment
Treatment Emergent Adverse Events (TEAE)
Tidsramme: 36-months of treatment

TEAE is an event that emerges during treatment, having been absent pretreatment, or worsens relative to the pretreatment state

36-months of treatment
Serious Adverse Events (SAE)
Tidsramme: 36-months of treatment

SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization, or prolongation of an existing hospitalization, results in persistent or significant disability or incapacity, is a birth defect or congenital anomaly

36-months of treatment

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Laurie Sanders, Ph.D., Duke Clinical Research Institute

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

9. januar 2026

Primær fullføring (Antatt)

1. september 2029

Studiet fullført (Antatt)

1. november 2029

Datoer for studieregistrering

Først innsendt

26. november 2025

Først innsendt som oppfylte QC-kriteriene

9. desember 2025

Først lagt ut (Faktiske)

16. desember 2025

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

30. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

28. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

UBESLUTTE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere